Conversely, the SPDR S&P Biotech ETF displays more volatility, like high-beta stocks.
"History suggests that while S&P is likely to continue rallying from here, high beta will not continue to outperform to the same degree," said Chintan Kotecha, an analyst at BAML, in a note to clients. The same up-then-down pattern has historically occurred within the biotech sector, and provides a way for traders to profit from a likely slowdown in high-beta stocks, Kotecha said.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »